Lakefront Biotherapeutics (LKFT)
29.52
-0.48
(-1.60%)
USD |
NASDAQ |
Oct 08, 16:00
29.52
0.00 (0.00%)
After-Hours: 20:00
Lakefront Biotherapeutics Net Income (Quarterly) : 2.260M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.260M |
| March 31, 2026 | 16.25M |
| December 31, 2025 | 910.76M |
| September 30, 2025 | -238.39M |
| June 30, 2025 | -118.39M |
| March 31, 2025 | -162.66M |
| December 31, 2024 | 20.40M |
| September 30, 2024 | -53.36M |
| June 30, 2024 | 5.018M |
| March 31, 2024 | 25.51M |
| September 30, 2023 | 47.37M |
| June 30, 2023 | 4.213M |
| March 31, 2023 | -12.01M |
| December 31, 2022 | -211.36M |
| September 30, 2022 | 21.70M |
| June 30, 2022 | -20.25M |
| March 31, 2022 | -14.93M |
| December 31, 2021 | 18.69M |
| September 30, 2021 | -76.16M |
| June 30, 2021 | -77.56M |
| March 31, 2021 | -15.45M |
| December 31, 2020 | -75.65M |
| September 30, 2020 | -96.39M |
| June 30, 2020 | -128.83M |
| March 31, 2020 | -57.57M |
| Date | Value |
|---|---|
| December 31, 2019 | -127.86M |
| September 30, 2019 | 401.63M |
| June 30, 2019 | -53.09M |
| March 31, 2019 | -55.25M |
| December 31, 2018 | 17.07M |
| September 30, 2018 | 17.26M |
| June 30, 2018 | -25.93M |
| March 31, 2018 | -45.82M |
| December 31, 2017 | -35.14M |
| September 30, 2017 | -43.32M |
| June 30, 2017 | -39.85M |
| March 31, 2017 | -14.57M |
| December 31, 2016 | 49.51M |
| September 30, 2016 | -27.03M |
| June 30, 2016 | -4.179M |
| March 31, 2016 | 39.64M |
| December 31, 2015 | -62.39M |
| September 30, 2015 | -30.32M |
| December 31, 2005 | -1.030M |
| September 30, 2005 | -2.777M |
| June 30, 2005 | 0.00 |
| March 31, 2005 | 0.00 |
| December 31, 2004 | 0.9927M |
| September 30, 2004 | -1.646M |
| June 30, 2004 | 0.00 |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Gilead Sciences, Inc. | -10.50B |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alkermes Plc | 0.501M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Amarin Corp. Plc | -7.664M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 14.08M |
| Total Expenses (Quarterly) | 11.82M |
| EPS Diluted (Quarterly) | 0.0349 |
| Enterprise Value | -583.55M |
| Gross Profit Margin (Quarterly) | 24.48% |
| Profit Margin (Quarterly) | 16.05% |
| Earnings Yield | 35.65% |
| Operating Earnings Yield | 34.75% |
| Normalized Earnings Yield | 45.23 |